Back to Search
Start Over
Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse.
- Source :
-
Oncoimmunology [Oncoimmunology] 2014 May 14; Vol. 3, pp. e28861. Date of Electronic Publication: 2014 May 14 (Print Publication: 2014). - Publication Year :
- 2014
-
Abstract
- Tyrosine kinase inhibitors have dramatically improved the treatment of chronic myeloid leukemia. Recent evidence revealed that some patients with chronic myeloid leukemia can stop imatinib without relapse after achieving a complete molecular response. This review discusses the possible predictive markers to identify these patients who can stop imatinib without relapse.
Details
- Language :
- English
- ISSN :
- 2162-4011
- Volume :
- 3
- Database :
- MEDLINE
- Journal :
- Oncoimmunology
- Publication Type :
- Academic Journal
- Accession number :
- 25057448
- Full Text :
- https://doi.org/10.4161/onci.28861